Breast Cancer | Specialty

Hormone Therapy in HER2+ Breast Cancer

February 5th 2021

Case Discussion 1: Resistance to a CDK4/6 Inhibitor

February 5th 2021

CDK4/6 Inhibitors for HR+ MBC: Data and Utilization

February 5th 2021

2020 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2021

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

Endoxifen Showcases Antitumor Activity in Breast Cancer, Phase 2 Trial Halted

February 3rd 2021

February 3, 2021 - Oral endoxifen, when delivered during the “window of opportunity” between diagnosis of breast cancer and surgery, resulted in a 74% average reduction in Ki-67 and Ki-67 levels lower than 25% at the time of surgery.

Trial Explores Preoperative Window for Amcenestrant Therapy in Early Breast Cancer

February 2nd 2021

Investigators are seeking to determine whether amcenestrant can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer.

Advantages of Oral Therapy for Metastatic Breast Cancer

February 2nd 2021

Chemotherapy to Treat MBC: Drug Developments

February 2nd 2021

De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo

January 29th 2021

Adjuvant Systemic Therapy Data Updates

January 29th 2021

Frontline Therapy for HR+ MBC: CDK4/6 Inhibitors

January 29th 2021

Evaluating Tumor Biology in HR+ Metastatic Breast Cancer

January 29th 2021

Dr. Moore on the Use of Preventive Anastrozole Versus Tamoxifen in DCIS

January 28th 2021

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Dr. Matsen on the Effects of Decreased Breast Cancer Screening in the COVID-19 Era

January 28th 2021

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

Metastatic Triple-Negative Breast Cancer

January 27th 2021

Metastatic Hormone Epidermal Growth Factor Receptor 2-Positive Breast Cancer

January 27th 2021

Metastatic Hormone-Receptor Positive Breast Cancer

January 27th 2021

Dr. Dumbrava on the Mechanism of Action of BDC-1001 in Advanced HER2-Expressing Breast Cancer

January 26th 2021

Ecaterina Ileana Dumbrava, MD, discusses the mechanism of action of BDC-1001 in advanced HER2-expressing breast cancer.

Predicting Response to Chemotherapy in Metastatic Breast Cancer

January 26th 2021

Metastatic Breast Cancer: Chemotherapy Selection

January 26th 2021